CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non

  CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial
  with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer

          Top-Line trial results expected in the second half of 2013

Business Wire

LOS ANGELES -- February 28, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that enrollment of 140 evaluable
patients has been completed in the Company’s global Phase 2b clinical trial
with its oral retinoid compound tamibarotene in combination with
chemotherapeutic agents as a first-line treatment for patients with advanced
non-small-cell lung cancer (NSCLC).

“Tamibarotene could represent a multi-billion dollar market opportunity as a
breakthrough in the treatment of NSCLC,” said CytRx CEO Steven A. Kriegsman.
“We are delighted to have reached this major milestone in the clinical trial
and expect to report top-line results from this trial in the second half of
this year.”

More deadly than colon, breast and prostate cancers combined, lung cancer has
a five-year survival rate of between 8-15%. Each year more than 220,000 new
cases of this cancer are reported in the U.S. and more than 1.5 million cases
reported worldwide. NSCLC accounts for approximately 85% of all lung cancers,
and by 2015, the market for this cancer is projected to reach $13.3 billion.

Patients with stage IIIB or IV squamous or adenocarcinoma NSCLC who had not
received prior non-adjuvant chemotherapy have been enrolled in the
double-blind Phase 2b trial in clinical sites in the U.S., Bulgaria, India,
Mexico, Russia and Ukraine. Patients are randomized for treatment in up to six
cycles with paclitaxel plus carboplatin, with half receiving tamibarotene and
half receiving placebo. The primary endpoint of the clinical trial is
progression-free survival, and secondary endpoints include response rate,
overall survival and RAR beta expression, a potential biomarker for
responders.

“We made the decision to pursue this indication due primarily to results from
a single-center Phase 2 clinical trial in which all trans-retinoic acid (ATRA)
added to a regimen of paclitaxel plus cisplatin produced far superior results
in late-stage NSCLC patients than a regimen of paclitaxel plus cisplatin
alone,” said Daniel Levitt, MD, Ph.D., CytRx’s Executive Vice President and
Chief Medical Officer. “In fact, response rates for patients receiving ATRA in
this trial increased two-fold, progression-free survival increased by three
months and median overall survival increased 14 months. Those results were
published in the July 2010 issue of the peer-reviewed Journal of Clinical
Oncology.”

Tamibarotene was developed to be superior to ATRA, an approved retinoid, by
binding to its molecular target more selectively. In preclinical models,
tamibarotene has proven to be 10 times more potent than ATRA with milder side
effects. CytRx holds the North American and European rights to certain
tamibarotene intellectual property for the treatment of NSCLC. Tamibarotene is
currently marketed in Japan for a rare form of leukemia.

AboutCytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline includes two programs in
clinical development for cancer indications: aldoxorubicin (formerly known
asINNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate
aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as
a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors and a
Phase 1b study of aldoxorubicin in combination with doxorubicin in patients
with advanced solid tumors. The Company has held a positive meeting with the
FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy, and has submitted a special protocol
assessment related to this trial. Tamibarotene is being tested in a
double-blind, placebo-controlled, international Phase 2b clinical trial in
patients with non-small-cell lung cancer. The Company completed its evaluation
of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in
high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a
partner for further development of bafetinib. For more information aboutCytRx
Corporation, visitwww.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements, including risks or uncertainties related to the
outcome, timing and results ofCytRx's Phase 2b clinical trial for
tamibarotene as a treatment for NSCLC, uncertainties regarding regulatory
approvals for current and future clinical testing of tamibarotene and the
scope of the clinical testing that may eventually be required by regulatory
authorities for tamibarotene, the significant time and expense that will be
incurred in developing any of the potential commercial applications for
tamibarotene, including for NSCLC, the risk that any future human testing of
tamibarotene for NSCLC might not produce results similar to those seen with
ATRA, risks related toCytRx'sability to manufacture its drug candidates,
including tamibarotene, in a timely fashion, cost-effectively or in commercial
quantities in compliance with stringent regulatory requirements, risks related
toCytRx'sneed for additional capital or strategic partnerships to fund its
ongoing working capital needs and development efforts, including any future
clinical development of tamibarotene, and the risks and uncertainties
described in the most recent annual and quarterly reports filed byCytRxwith
theSecurities and Exchange Commissionand current reports filed since the
date ofCytRx'smost recent annual report. All forward-looking statements are
based upon information available toCytRxon the date the statements are first
published.CytRxundertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com